<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002003</url>
  </required_header>
  <id_info>
    <org_study_id>055A</org_study_id>
    <secondary_id>3-100</secondary_id>
    <nct_id>NCT00002003</nct_id>
  </id_info>
  <brief_title>Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas</brief_title>
  <official_title>Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lederle Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride (&#xD;
      Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Positive HIV antibody, positive HIV culture or antigen capture, or prior diagnosis of&#xD;
             AIDS by the CDC criteria.&#xD;
&#xD;
          -  Diagnosis by pathological examination of large cell or immunoblastic lymphoma within&#xD;
             measurable or evaluable disease.&#xD;
&#xD;
          -  Pneumocystis carinii pneumonia (PCP) prophylaxis during the course of the study.&#xD;
&#xD;
          -  Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia&#xD;
             (PCP) diagnosed within 3 weeks.&#xD;
&#xD;
          -  Stage IE Central Nervous System lymphomas.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  More than one previous treatment for lymphoma.&#xD;
&#xD;
          -  Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia&#xD;
             (PCP) diagnosed within 3 weeks.&#xD;
&#xD;
          -  Conditions that preclude obtaining an informed consent.&#xD;
&#xD;
          -  Not accessible for scheduled treatment visits or follow-up.&#xD;
&#xD;
          -  Stage IE Central Nervous System (CNS) lymphomas.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Zidovudine.&#xD;
&#xD;
          -  Excluded:&#xD;
&#xD;
          -  Doxorubicin dosing = or &gt; 300 mg/m2.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Received more than one previous treatment regimen for lymphoma.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Prophylactic treatment for Pneumocystis carinii pneumonia (PCP) prophylaxis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UMDNJ - New Jersy Med School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>071032714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's - Roosevelt Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 1992</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Mitoxantrone</keyword>
  <keyword>Lymphoma, Large-Cell</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

